BRPI0413500A - compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade - Google Patents
compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidadeInfo
- Publication number
- BRPI0413500A BRPI0413500A BRPI0413500-8A BRPI0413500A BRPI0413500A BR PI0413500 A BRPI0413500 A BR PI0413500A BR PI0413500 A BRPI0413500 A BR PI0413500A BR PI0413500 A BRPI0413500 A BR PI0413500A
- Authority
- BR
- Brazil
- Prior art keywords
- obesity
- compounds
- treatment
- prophylaxis
- arthritis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMPOSTOS, PROCESSO PARA A SUA PREPARAçãO, COMPOSIçãO FARMACêUTICA QUE COMPREENDE OS MESMOS, UTILIZAçãO DE UM COMPOSTO, MéTODO PARA O TRATAMENTO E PROFILAXIA DE ARTRITE, DIABETES, DISTúRBIOS ALIMENTARES E OBESIDADE". Expõem-se compostos da fórmula I bem como os seus sais e ésteres farmaceuticamente aceitáveis, em que R¬ 1¬ a R¬ 5¬, a e b têm os significados apresentados na reivindicação 1, os quais podem ser usados na forma de composições farmacêuticas como ligantes de neuropeptídeos e receptores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03017634 | 2003-08-12 | ||
PCT/EP2004/008698 WO2005014592A1 (en) | 2003-08-12 | 2004-08-04 | 2-amino-5-benzoylthiazole npy antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413500A true BRPI0413500A (pt) | 2006-10-10 |
Family
ID=34130066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413500-8A BRPI0413500A (pt) | 2003-08-12 | 2004-08-04 | compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade |
Country Status (14)
Country | Link |
---|---|
US (1) | US7250431B2 (pt) |
EP (1) | EP1658288B1 (pt) |
JP (1) | JP2007501823A (pt) |
KR (1) | KR20060037435A (pt) |
CN (1) | CN100422179C (pt) |
AT (1) | ATE380189T1 (pt) |
AU (1) | AU2004263311A1 (pt) |
BR (1) | BRPI0413500A (pt) |
CA (1) | CA2533463A1 (pt) |
DE (1) | DE602004010529T2 (pt) |
ES (1) | ES2297437T3 (pt) |
MX (1) | MXPA06001570A (pt) |
RU (1) | RU2006107444A (pt) |
WO (1) | WO2005014592A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005000858A1 (de) * | 2005-01-05 | 2006-07-20 | Merck Patent Gmbh | Fluortenside |
AU2006331656B2 (en) * | 2005-12-22 | 2012-08-09 | Icagen, Inc. | Calcium channel antagonists |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
KR101668514B1 (ko) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
US4776409A (en) | 1984-09-04 | 1988-10-11 | Manchak Frank | Insitu waste impoundment treating apparatus and method of using same |
US4844839A (en) | 1984-09-04 | 1989-07-04 | Manchak Frank | In situ treatment and analysis of wastes |
CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
US5246960A (en) | 1984-12-21 | 1993-09-21 | Hoffmann-La Roche Inc. | Oxetanones |
CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
GB2191186B (en) | 1985-08-26 | 1989-11-01 | Manchak Frank | In situ hazardous waste treating apparatus and method of using same |
CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
DK1105122T3 (da) | 1998-08-14 | 2005-08-08 | Hoffmann La Roche | Pharmaceutical compositions containing lipase inhibitors |
ES2217797T3 (es) | 1998-08-14 | 2004-11-01 | F. Hoffmann-La Roche Ag | Vinileteres heterociclicos contra trastornos neurologicos. |
AU2003210305B2 (en) * | 2002-02-28 | 2006-07-06 | F. Hoffmann-La Roche Ag | Thiazole derivatives as NPY receptor antagonists |
CA2493712A1 (en) * | 2002-08-07 | 2004-02-19 | F. Hoffmann-La Roche Ag | Aminothiazole derivatives as npy5 receptor inhibitors |
-
2004
- 2004-08-04 AT AT04741359T patent/ATE380189T1/de not_active IP Right Cessation
- 2004-08-04 KR KR1020067002829A patent/KR20060037435A/ko active IP Right Grant
- 2004-08-04 ES ES04741359T patent/ES2297437T3/es active Active
- 2004-08-04 MX MXPA06001570A patent/MXPA06001570A/es not_active Application Discontinuation
- 2004-08-04 AU AU2004263311A patent/AU2004263311A1/en not_active Abandoned
- 2004-08-04 EP EP04741359A patent/EP1658288B1/en not_active Not-in-force
- 2004-08-04 JP JP2006522949A patent/JP2007501823A/ja active Pending
- 2004-08-04 BR BRPI0413500-8A patent/BRPI0413500A/pt not_active IP Right Cessation
- 2004-08-04 CN CNB2004800230173A patent/CN100422179C/zh not_active Expired - Fee Related
- 2004-08-04 CA CA002533463A patent/CA2533463A1/en not_active Abandoned
- 2004-08-04 DE DE602004010529T patent/DE602004010529T2/de active Active
- 2004-08-04 WO PCT/EP2004/008698 patent/WO2005014592A1/en active IP Right Grant
- 2004-08-04 RU RU2006107444/04A patent/RU2006107444A/ru not_active Application Discontinuation
- 2004-08-10 US US10/915,199 patent/US7250431B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2297437T3 (es) | 2008-05-01 |
CN100422179C (zh) | 2008-10-01 |
EP1658288A1 (en) | 2006-05-24 |
ATE380189T1 (de) | 2007-12-15 |
WO2005014592A1 (en) | 2005-02-17 |
KR20060037435A (ko) | 2006-05-03 |
US20050038089A1 (en) | 2005-02-17 |
RU2006107444A (ru) | 2007-09-20 |
CA2533463A1 (en) | 2005-02-17 |
AU2004263311A1 (en) | 2005-02-17 |
DE602004010529T2 (de) | 2008-11-27 |
CN1852907A (zh) | 2006-10-25 |
DE602004010529D1 (de) | 2008-01-17 |
US7250431B2 (en) | 2007-07-31 |
EP1658288B1 (en) | 2007-12-05 |
MXPA06001570A (es) | 2006-05-15 |
JP2007501823A (ja) | 2007-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2596434T3 (es) | Moduladores de receptores opioides | |
MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
BRPI0718714B8 (pt) | arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende | |
NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
BRPI0411936A (pt) | composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade | |
UY27300A1 (es) | Nuevos derivados de quinolina | |
UY27646A1 (es) | Derivados de quinolina como antagonistas de npt | |
BRPI0417376A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização | |
BRPI0409454A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com o receptor de glucagon e sua utilização | |
WO2003004480A3 (en) | Substituted piperazine and diazepanes as histamine h3 receptor agonists | |
ECSP088405A (es) | Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer | |
CY1109787T1 (el) | Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις | |
DK1856090T3 (da) | Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
BRPI0519106A2 (pt) | compostos, uso destes, processo para sua fabricaÇço, composiÇÕes farmacÊuticas, mÉtodo para o tratamento e/ou profilaxia de doenÇas que sço associadas com a dpp-iv | |
NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
ATE459619T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
AR120703A1 (es) | Formas sólidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-amina de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico | |
BRPI0413500A (pt) | compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
MXPA04002825A (es) | Derivados de quinolina como antagonistas de neuropeptido y. | |
BRPI0507120A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização | |
TW200616958A (en) | New alkyl-pyridines as 11-beta inhibitors for diabetes | |
WO2005118579A3 (en) | Thiazole derivatives as chemokine receptor antagonists | |
ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |